Skip Main Navigation | Skip to Content

News of the Week Home

News of the Week

Blaber to collaborate with NIH on Fuchs Dystrophy drug

Biomedical Sciences Professor and Trefoil Therapeutics Co-Founder Michael Blaber will collaborate with the NIH’s National Center for Advancing Translational Sciences (NCATS) to continue developing a treatment for Fuchs endothelial corneal dystrophy (FECD). FECD can lead to severe vision loss, and there is currently no FDA-approved therapy. Trefoil Therapeutics will participate in the NCATS Therapeutics for Rare and Neglected Diseases program to significantly accelerate the development of the drug.